Tigecycline: a novel glycylcycline

Related Experiment Video

Updated: Aug 17, 2026

Assay Development for High-Throughput Drug Screening Against Mycobacteria
07:50

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

Ethan Rubinstein1, David Vaughan

  • 1Section of Infectious Diseases, University of Manitoba, Winnipeg, Manitoba, Canada. erubins@yahoo.com

Drugs
|June 28, 2005
PubMed

Insights

Tigecycline, a novel glycylcycline antibacterial, shows potent activity against multidrug-resistant pathogens. Clinical trials demonstrate its efficacy in treating serious infections with manageable side effects, supporting its role in combating bacterial resistance.

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Microbiology

Background:

  • Bacterial resistance to existing antibacterials is a growing global health concern.
  • Tigecycline represents a new class of antibacterials, glycylcyclines, developed to address this challenge.
  • Multidrug-resistant pathogens pose a significant threat in both hospital and community settings.

Purpose of the Study:

  • To evaluate the efficacy and safety of tigecycline, a novel glycylcycline antibacterial.
  • To assess tigecycline's activity against a broad spectrum of clinically relevant pathogens, including resistant strains.
  • To understand the pharmacokinetic and pharmacodynamic properties of tigecycline.

Main Methods:

  • Phase III human clinical trials were conducted to assess therapeutic response.
  • Microbiological activity was evaluated against various Gram-positive, Gram-negative, and anaerobic pathogens.
  • Animal infection models were used to study efficacy in conditions like pneumonia and peritonitis.
  • Pharmacokinetic parameters including volume of distribution, clearance, and half-life were determined.

Main Results:

  • Tigecycline demonstrated potent activity against susceptible and multidrug-resistant staphylococci, enterococci, streptococci, Enterobacteriaceae, and anaerobic pathogens.
  • Phase III trials showed excellent therapeutic response in intra-abdominal and skin/soft tissue infections.
  • Nausea and vomiting were the most common adverse events, comparable to other tetracyclines.
  • Efficacy was confirmed in various animal infection models.

Conclusions:

  • Tigecycline exhibits a favorable efficacy and safety profile for treating complex infections.
  • Its broad spectrum of activity, including against resistant pathogens, makes it a valuable therapeutic option.
  • Pharmacokinetic data and correlation of time above minimum inhibitory concentration with bacterial eradication support its clinical development.
  • Tigecycline is a promising empirical parenteral treatment for challenging nosocomial and community-acquired infections.

More Related Videos

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach10:01

Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach

Published on: June 23, 2026

Related Concept Videos

Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
Inhibitors of Gram-positive Cell Wall Synthesis01:23

Inhibitors of Gram-positive Cell Wall Synthesis

Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Cytoskeletal Proteins in Bacteria01:29

Cytoskeletal Proteins in Bacteria

Bacterial cells were initially considered simple, randomly organized structures lacking a cytoskeleton. However, the discovery of cytoskeleton homologs in bacteria led to the change of this opinion. Bacterial cytoskeletal filaments regulate the cell shape, cell polarity, cell division, and partitioning of plasmids during cell division. It was later discovered that bacterial cytoskeletal proteins, mainly actin and tubulin homologs, are diverse compared to their eukaryotic counterparts. On the...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...